Business Context and Reporting Period
CareDx, Inc. (CDNA) filed a Form 8-K on April 24, 2026, reporting significant corporate actions and financial updates. The filing covers events occurring between April 24, 2026, and April 28, 2026, including the announcement of Q1 2026 financial results and the authorization of a new stock repurchase program.
Key Financial Metrics and Transaction Details
Acquisition of Naveris, Inc.
- Base Consideration: $160.0 million in cash, subject to customary adjustments for cash, indebtedness, transaction expenses, and working capital.
- Contingent Consideration: Up to $100.0 million in additional cash based on revenue milestones for fiscal years ending December 31, 2026, and December 31, 2027.
- Escrow: $5.0 million of the closing consideration will be held in escrow to secure post-closing purchase price adjustments.
- Structure: Merger Sub (a wholly owned subsidiary of CareDx) will merge with Naveris, with Naveris surviving as a wholly owned subsidiary.
Stock Repurchase Program
- Authorization: $100 million in common stock repurchases.
- Duration: Valid for 24 months from April 30, 2026.
- Funding: To be funded from existing cash, cash equivalents, or future cash flow.
- Context: This is separate from a prior $50 million program authorized in May 2025.
Financial Results
The filing references a press release (Exhibit 99.1) containing Q1 2026 results but does not provide specific revenue, profit, cash flow, or margin figures within the text of this 8-K.
Material Changes and Conditions
The primary material change is the entry into a definitive merger agreement to acquire Naveris, Inc. The transaction is subject to customary closing conditions, including:
- Expiration of the Hart-Scott-Rodino Antitrust waiting period.
- Accuracy of representations and warranties.
- Performance of covenants by both parties.
- Absence of a material adverse effect on Naveris.
- Receipt of requisite written stockholder consent from Naveris within 24 hours of execution.
The agreement includes termination rights if the transaction is not consummated by October 28, 2026, subject to automatic extensions under specified circumstances.
Guidance, Outlook, and Risks
Outlook and Commentary
Management has issued forward-looking statements regarding the anticipated benefits and timing of the Naveris transaction. The company also posted an updated corporate presentation on its website as of April 28, 2026.
Risks and Contingencies
- Transaction Failure: Risks include failure to satisfy closing conditions, inability to obtain regulatory approvals, or termination of the Merger Agreement.
- Timing: The transaction may not be completed on the anticipated timeline or at all.
- Repurchase Discretion: The stock repurchase program does not obligate the company to acquire a specific number of shares and may be suspended or discontinued at any time.
Investor Verification Checklist
- Verify the specific Q1 2026 revenue and net income figures in the attached Press Release (Exhibit 99.1), as they are not detailed in the 8-K text.
- Review the full text of the Merger Agreement (Exhibit 2.1) for detailed representations, warranties, and specific milestone definitions for the $100 million contingent consideration.
- Monitor regulatory filings for the status of the Hart-Scott-Rodino waiting period and any required antitrust approvals.
- Confirm the status of Naveris stockholder consent, which is a condition precedent for closing.
- Assess the impact of the $160 million cash outlay and potential $100 million contingent liability on CareDx's current liquidity and cash reserves.